Amgen CEO Buys Two Estates on Malibu’s Point Dume

Last year, Bob Bradway took home more than $21 million in total compensation, making him one of the United States’ highest paid CEOs. But that hasn’t stopped the Harvard MBA and longtime Amgen chief from embarking on a lucrative side hustle, investing those rewards in prime rental real estate. Records reveal Bradway recently bought two impressive properties on Malibu’s Point Dume, both of which have been leased out for huge sums of money.

Bradway’s first seaside splurge came in February 2021, when he paid about $5.2 million for what the listing called an “original Point Dume compound” on nearly a full flat acre. The 1950s property includes multiple structures — a three-bedroom main house, two-bed guesthouse with its own kitchen, a separate studio and a detached garage and yoga room. Altogether, the assemblage of modest buildings totals 2,500 square feet of living space.

Dated listings indicate that since Bradway’s acquisition, the Point Dume estate has been leased out for $16,000 per month; one of the tenants is believed to have been musician Rob Bourdon, drummer and co-founder of the rock band Linkin Park.

Earlier this year, Bradway paid exactly $7 million to buy another Malibu residence, this one sited on one of Point Dume’s most expensive streets. Like Bradway’s other Point Dume pad, this place is completely landlocked, though the roughly 2,500-square-foot, early 1970s ranch house does sport ocean views from its elevated perch. And like the other property, this home has also been put up for lease since Bradway’s acquisition — most recently at a rental rate of $15,000/month.

Besides their two investment properties in Malibu, Bradway and his longtime wife Michelle Kay continue to own their main residence — a midcentury ranch-style estate set on nearly 40 acres in the Hidden Valley region, on the far outskirts of Los Angeles. From there, Bradway is a short commute from Amgen’s headquarters in the city of Thousand Oaks.

Bradway, 59, has been CEO of Amgen since 2012. He’s been with the pharmaceutical giant since 2006; in that time, his personal net worth has swelled to more than $175 million, per stock investments tracker Wallmine.